Publications by authors named "Yudai Matsuura"
The potential involvement of the gut microbiota in metabolic dysfunction-associated steatohepatitis (MASH) pathogenesis has garnered increasing attention. In this study, we elucidated the link between high-fat/cholesterol/cholate-based (iHFC)#2 diet-induced MASH progression and gut microbiota in C57BL/6 mice using antibiotic treatments. Treatment with vancomycin (VCM), which targets gram-positive bacteria, exacerbated the progression of liver damage, steatosis, and fibrosis in iHFC#2-fed C57BL/6 mice.
View Article and Find Full Text PDFBackground: Tsumura-Suzuki non-obese (TSNO) mice exhibit a severe form of metabolic dysfunction-associated steatohepatitis (MASH) with advanced liver fibrosis upon feeding a high-fat/cholesterol/cholate-based (iHFC) diet. Another ddY strain, Tsumura-Suzuki diabetes obese (TSOD) mice, are impaired in the progression of iHFC diet-induced MASH.
Aim: To elucidate the underlying mechanisms contributing to the differences in MASH progression between TSNO and TSOD mice.
Article Synopsis
- Macrophages play a crucial role in the progression of non-alcoholic steatohepatitis (NASH), with specific subsets exhibiting either pro-fibrotic or anti-inflammatory properties in the liver.
- An iHFC diet with reduced cholic acid (iHFC#2) was found to induce signs of NASH, including inflammation and fibrosis, in C57BL/6 mice, leading to changes in macrophage populations in the liver.
- The study revealed that different diets and mouse strains affect the types and behavior of macrophages that accumulate in the liver, highlighting the complexity of NASH pathology.